Title : Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.

Pub. Date : 2014 Sep

PMID : 24942275






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 FOLFIRI plus cetuximab treatment determined ORR of 62.0% (95% CI 55.5% to 74.6%) with mPFS of 11.1 (95% CI 9.2-12.8) months in patients with KRAS and NRAS wild-type tumors. FOLFIRI regimen KRAS proto-oncogene, GTPase Homo sapiens
2 FOLFIRI plus cetuximab treatment determined ORR of 62.0% (95% CI 55.5% to 74.6%) with mPFS of 11.1 (95% CI 9.2-12.8) months in patients with KRAS and NRAS wild-type tumors. FOLFIRI regimen NRAS proto-oncogene, GTPase Homo sapiens